ARTICLE | Clinical News
Xtandi enzalutamide: Phase II data
April 13, 2015 7:00 AM UTC
Top-line data from the double-blind, U.S. Phase II STRIVE trial in 396 patients with CRPC showed that once-daily 160 mg oral Xtandi met the primary endpoint of improving median PFS vs. once-daily 50 m...